Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rocio D Marchese

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Clinical and Vaccine Immunology : CVI|August 5, 2011
Comparison of a new multiplex binding assay versus the enzyme-linked immunosorbent assay for measurement of serotype-specific pneumococcal capsular polysaccharide IgGDavid Goldblatt, Lindsey Ashton, Yuhua Zhang, et al.
Journal of Immunoassay & Immunochemistry|September 30, 2008
Complexities of clinical assay development and optimization prior to first-in-man immunization trials - a description of immunogenicity assay development for the testing of samples from a phase 1 Alzheimer's vaccine trialOlivia Hammond, James Reynolds, Leonard J Rubinstein, et al.
Pediatric Transplantation|February 12, 2009
Sustainability of humoral responses to varicella vaccine in pediatric transplant recipients following a pretransplantation immunization strategyMichelle Barton, Samia Wasfy, Toni Melbourne, et al.
Vaccine|January 18, 2003
Memory T cells and vaccinesMark T Esser, Rocio D Marchese, Lisa S Kierstead, et al.
Clinical and Vaccine Immunology : CVI|January 23, 2009
Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serumRocio D Marchese, Derek Puchalski, Pamela Miller, et al.
Journal of Medical Virology|October 26, 2006
The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detectionOlivia Hammond, Yue Wang, Tina Green, et al.
Human Vaccines|August 24, 2011
Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adultsDaniel M Musher, Susan B Manoff, Richard D McFetridge, et al.
The Journal of Infectious Diseases|January 23, 2010
Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adultsDaniel M Musher, Susan B Manof, Charlie Liss, et al.
Clinical and Vaccine Immunology : CVI|August 9, 2006
Enzyme-linked immunosorbent assay for measuring antibodies to pneumococcal polysaccharides for the PNEUMOVAX 23 vaccine: assay operating characteristics and correlation to the WHO international assayRocio D Marchese, Neil T Jain, Joseph Antonello, et al.
Vaccine|March 22, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of ageSusan J Ermlich, Charles P Andrews, Steven Folkerth, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Clinical and Vaccine Immunology : CVI|August 5, 2011
Comparison of a new multiplex binding assay versus the enzyme-linked immunosorbent assay for measurement of serotype-specific pneumococcal capsular polysaccharide IgGDavid Goldblatt, Lindsey Ashton, Yuhua Zhang, et al.
Journal of Immunoassay & Immunochemistry|September 30, 2008
Complexities of clinical assay development and optimization prior to first-in-man immunization trials - a description of immunogenicity assay development for the testing of samples from a phase 1 Alzheimer's vaccine trialOlivia Hammond, James Reynolds, Leonard J Rubinstein, et al.
Pediatric Transplantation|February 12, 2009
Sustainability of humoral responses to varicella vaccine in pediatric transplant recipients following a pretransplantation immunization strategyMichelle Barton, Samia Wasfy, Toni Melbourne, et al.
Vaccine|January 18, 2003
Memory T cells and vaccinesMark T Esser, Rocio D Marchese, Lisa S Kierstead, et al.
Clinical and Vaccine Immunology : CVI|January 23, 2009
Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serumRocio D Marchese, Derek Puchalski, Pamela Miller, et al.
Journal of Medical Virology|October 26, 2006
The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detectionOlivia Hammond, Yue Wang, Tina Green, et al.
Human Vaccines|August 24, 2011
Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adultsDaniel M Musher, Susan B Manoff, Richard D McFetridge, et al.
The Journal of Infectious Diseases|January 23, 2010
Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adultsDaniel M Musher, Susan B Manof, Charlie Liss, et al.
Clinical and Vaccine Immunology : CVI|August 9, 2006
Enzyme-linked immunosorbent assay for measuring antibodies to pneumococcal polysaccharides for the PNEUMOVAX 23 vaccine: assay operating characteristics and correlation to the WHO international assayRocio D Marchese, Neil T Jain, Joseph Antonello, et al.
Vaccine|March 22, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of ageSusan J Ermlich, Charles P Andrews, Steven Folkerth, et al.
Pageof 2